|
|
|
|
|
|
|
NOT AVAILABLE IN THE US
|
Helicobacter Pylori, a major cause of chronic gastritis, is strongly associated with the development of
gastric and duodenal ulcers and has been linked with gastric adenocarcinoma and B-cell mucosa-associated
lymphoid tissue lymphoma. Current treatment of H. pylori infection consists of a triple or quadruple regimen
that includes antibiotics and a proton inhibitor, such as amoxicillin and clarithromycin. Among these, the
presence of clarithromycin-resistant H. pylori has been found, which has presented a serious obstacle to the
treatment of H. pylori using clarithromycin. Thus, the detection of clarithromycin-resistant H. pylori is
needed to increase the efficiency of the treatment and to prescribe other antibiotics, by diagnosing the
presence of clarithromycin-resistant H. pylori before treatment with antibiotics. Most clarithromycin-
resistant H. pylori have point mutation at the 2142 and 2143 base sequences of the 23S rRNA gene, and exist as
A2142G and A2143G, respectively.
Seeplex® ClaR-H. pylori ACE Detection has been developed to detect these two kinds of point mutations
specifically using DPO™ technology. |
 |
| A. |
Identification of two point mutations (A2143G & A2142G), which cause
clarithromycin resistance in H. pylori, without culture |
| B. |
Multiplex PCR with high sensitivity and specificity by applying DPO™ (Dual Priming Oligonucleotide) technology |
| C. |
Applicable for Auto-capillary Electrophoresis device |
| D. |
Contamination Prevention System |
|
 |
- H. pylori
- A2143G |
|
- A2142G
|
 |
 |
ScreenTape®
System
(Agilent
Technologies)
 |
 |
MCE®-202
MultiNA
SHIMADZU
|
|
|
|
 |
| Product |
Cat. No. |
Size |
| Seeplex® ClaR-H. pylori ACE Detection |
HC1210Z |
25 rxns |
|
|
|
|
|
|
